Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions

This study has been completed.
Sponsor:
Information provided by:
Akron Children's Hospital
ClinicalTrials.gov Identifier:
NCT00592657
First received: January 1, 2008
Last updated: July 25, 2008
Last verified: July 2008
  Purpose

Retrospective chart review to determine the presence of rhabdomyolysis among patients admitted to CHMCA from 1997-2007 with Jimsonweed ingestions and to define possible risk factors predisposing patients to the developement of Jimsonweed-associated rhabdomyolysis.


Condition
Rhabdomyolysis
Myoglobinuria
Hemoglobinuria

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Incidence of Rhabdomyolysis Among Pediatric and Adolescent Patients Admitted for Jimsonweed (Datura Stramonium) Ingestions

Resource links provided by NLM:


Further study details as provided by Akron Children's Hospital:

Primary Outcome Measures:
  • The presence of rhabdomyolysis based on serum CK concentrations in patients admitted with history of Jimsonweed ingestion. [ Time Frame: From admission until discharge ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Renal function, liver function, vital signs, physical exam [ Time Frame: From admission until discharge ] [ Designated as safety issue: Yes ]

Enrollment: 46
Study Start Date: January 2008
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
2
Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion

  Eligibility

Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed with rhabdomyolysis/ myoglobinuria/ hemoglobinuria (in-patient, out-patient, ER visit) at a CHMCA facility

Criteria

Inclusion Criteria:

  • admitted to CHMCA between 1/1/1997 to 12/31/2007 with a qualifying ICD-9 diagnosis code for rhabdomyolysis, myoglobinuria, and hemoglobinuria (728.88, 791.2, 791.3)or other ICD-9 codes identified during the study
  • between the ages of 0-21 years at diagnosis

Exclusion Criteria:

  • rhabdomyolysis or serum CK concentrations not actually documented
  • patient admitted to the burn center
  • patient > 21 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00592657

Locations
United States, Ohio
Children's Hospital Medical Center of Akron
Akron, Ohio, United States, 44308
Sponsors and Collaborators
Akron Children's Hospital
Investigators
Principal Investigator: Martha Blackford CHMCA
  More Information

Publications:
Responsible Party: Martha Blackford PharmD, CHMCA
ClinicalTrials.gov Identifier: NCT00592657     History of Changes
Other Study ID Numbers: JIMSONWEED
Study First Received: January 1, 2008
Last Updated: July 25, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Akron Children's Hospital:
retrospective chart review
Jimsonweed ingestion

Additional relevant MeSH terms:
Hemoglobinuria
Myoglobinuria
Rhabdomyolysis
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on July 22, 2014